Anti-TNR17/ TNFRSF17/ BCM monoclonal antibody

Anti-TNR17/ TNFRSF17/ BCM antibody for FACS & in-vivo assay

Target products collectionGo to TNFRSF17/TNFRSF17 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T66693-Ab-1/ GM-Tg-hg-T66693-Ab-2Anti-Human TNFRSF17 monoclonal antibodyHuman
GM-Tg-rg-T66693-Ab-1/ GM-Tg-rg-T66693-Ab-2Anti-Rat TNFRSF17 monoclonal antibodyRat
GM-Tg-mg-T66693-Ab-1/ GM-Tg-mg-T66693-Ab-2Anti-Mouse TNFRSF17 monoclonal antibodyMouse
GM-Tg-cynog-T66693-Ab-1/ GM-Tg-cynog-T66693-Ab-2Anti-Cynomolgus/ Rhesus macaque TNFRSF17 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T66693-Ab-1/ GM-Tg-felg-T66693-Ab-2Anti-Feline TNFRSF17 monoclonal antibodyFeline
GM-Tg-cang-T66693-Ab-1/ GM-Tg-cang-T66693-Ab-2Anti-Canine TNFRSF17 monoclonal antibodyCanine
GM-Tg-bovg-T66693-Ab-1/ GM-Tg-bovg-T66693-Ab-2Anti-Bovine TNFRSF17 monoclonal antibodyBovine
GM-Tg-equg-T66693-Ab-1/ GM-Tg-equg-T66693-Ab-2Anti-Equine TNFRSF17 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T66693-Ab-1/ GM-Tg-hg-T66693-Ab-2; GM-Tg-rg-T66693-Ab-1/ GM-Tg-rg-T66693-Ab-2;
GM-Tg-mg-T66693-Ab-1/ GM-Tg-mg-T66693-Ab-2; GM-Tg-cynog-T66693-Ab-1/ GM-Tg-cynog-T66693-Ab-2;
GM-Tg-felg-T66693-Ab-1/ GM-Tg-felg-T66693-Ab-2; GM-Tg-cang-T66693-Ab-1/ GM-Tg-cang-T66693-Ab-2;
GM-Tg-bovg-T66693-Ab-1/ GM-Tg-bovg-T66693-Ab-2; GM-Tg-equg-T66693-Ab-1/ GM-Tg-equg-T66693-Ab-2
Products NameAnti-TNFRSF17 monoclonal antibody
Formatmab
Target NameTNFRSF17
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-TNFRSF17 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-INN-752Pre-Made Belantamab Mafodotin Biosimilar, Whole Mab Adc, Anti-Tnfrsf17 Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A therapeutic antibody Drug Conjugate
    BiosimilarGMP-Bios-ab-663Pre-Made Elranatamab biosimilar, Whole mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody
    BiosimilarGMP-Bios-ab-433Pre-Made Pavurutamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody
    BiosimilarGMP-Bios-ab-055Pre-Made Belantamab biosimilar, Whole mAb ADC, Anti-TNFRSF17 Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A therapeutic antibody
    BiosimilarGMP-Bios-ab-421Pre-Made Pacanalotamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody
    BiosimilarGMP-Bios-ab-018Pre-Made Alnuctamab biosimilar, Bispecific mAb with Domain Crossover, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody
    BiosimilarGMP-Bios-ab-557Pre-Made Teclistamab biosimilar, Bispecific mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species TNR17/ TNFRSF17/ BCM VLP (virus-like particle) (Products Developing)
    CytokineGM-Tg-g-T66693-Ag-1tumor necrosis factor receptor superfamily, member 17 (TNFRSF17) protein
    ORF Viral VectorpGMLP004529human TNFRSF17 Lentivirus plasmid
    ORF Viral VectorvGMLP004529human TNFRSF17 Lentivirus particle
    ORF Viral VectorpGMLPm000287mouse Tnfrsf17 Lentivirus plasmid
    ORF Viral VectorvGMLPm000287mouse Tnfrsf17 Lentivirus particle


    Target information

    Target IDGM-T66693
    Target NameTNFRSF17
    Gene ID608,21935,287034,712212,100684674,101086618,784268,100055833
    Gene Symbol and SynonymsBCM,BCMA,CD269,Tnfrsf13,TNFRSF13A,TNFRSF17
    Uniprot AccessionQ02223
    Uniprot Entry NameTNR17_HUMAN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target
    DiseaseCancer
    Gene EnsemblENSG00000048462
    Target ClassificationCheckpoint-Immuno Oncology, Immune cell receptor, Tumor-associated antigen (TAA)

    The target: TNFRSF17, gene name: TNFRSF17, also named as BCM, BCMA, CD269, TNFRSF13A. The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.